Chengdu, China, April 10, 2024
Anticancer Bioscience unveils groundbreaking MYC-Synthetic Lethal Therapy at AACR 2024
Chengdu, China, April 10, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that their research team at the 2024 AACR Conference introduced a pioneering therapy aimed at cancer with the deregulated MYC oncogene. The novel treatment, JMBI-001, is a multifaceted, orally administered small-molecule inhibitor that has demonstrated exceptional efficacy in a wide range of preclinical studies. It selectively targets and eradicates tumor cells overexpressing the MYC oncogene. Additionally, JMBI-001 not only elicits a robust systemic antitumor immune response by directly acting on cancer cells but also shows increased effectiveness when used in combination with anti-PD1 therapy. It has proven to be well-tolerated in both small and large animal models. This new approach is a major advance in treating MYC-driven cancers, which have been challenging to target with existing therapies.
About Anticancer Bioscience
Anticancer Bioscience (ACB) is an international private company commercializing discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. ACB is based on over 20 years of collaborative research between the founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop. It has raised CNY131M (around USD21M) and has around 50 employees in Chengdu, China, Hyderabad, India, Sydney, Australia, St Andrews, UK, and San Francisco, USA.
